AB Science (ABSCF) Stock Price, News & Analysis

Company Overview

AB Science is a France-based biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for human and veterinary medicine. The company’s research centers on tyrosine kinase inhibitors, a class of medicines designed to modulate signaling pathways involved in cancer, inflammation and other diseases.

Its lead product is masitinib, an orally administered tyrosine kinase inhibitor that targets pathways involving mast cells and certain other immune and tumor-related cells. Masitinib has been evaluated in a range of human conditions, including oncology, neurodegenerative diseases and inflammatory disorders. The company has also developed Masivet, a veterinary formulation of masitinib authorized in the European Union for the treatment of certain canine mast cell tumors.

Founded in 2001, AB Science is headquartered in Paris, France, and conducts research and clinical development activities in France and other international markets through clinical studies and regulatory programs. Alain Moussy is the company’s co-founder and chief executive officer. AB Science is listed on Euronext Paris and its shares also trade in the United States under the symbol ABSCF.

Key Stats

• Today's Range: $1.12 to $1.12
• 50-Day Range: $1.12 to $1.12
• 52-Week Range: $1.12 to $1.37
• Volume: N/A
• Average Volume: 146 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ABSCF
• CIK: N/A
• Web: www.ab-science.com
• Phone: (314) 720-0014
• Fax: N/A
• Employees: 51
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A